Endometrial Cancer Clinical Trials

110 studies are recruiting for endometrial cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

   This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Cancer Institute, Detroit, Michigan

   Locations

   11 in total

   Run by

   Sairopa B.V.

   See if you can join NCT05856981 on ClinicalTrials.gov

2. Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

   The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   USAH Mitchell Cancer Inst, Mobile, Alabama

   Locations

   178 in total

   Run by

   Genmab

   See if you can join NCT07166094 on ClinicalTrials.gov

3. Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

   This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Los Angeles, Los Angeles, California

   Locations

   6 in total

   Run by

   Regor Pharmaceuticals Inc.

   See if you can join NCT07524322 on ClinicalTrials.gov

4. CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

   The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Clinical Study Site, Austin, Texas

   Locations

   3 in total

   Run by

   Crescent Biopharma, Inc.

   See if you can join NCT07909031 on ClinicalTrials.gov

5. EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

   The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   California Research Institute (CRI), Los Angeles, California

   Locations

   45 in total

   Run by

   Eikon Therapeutics

   See if you can join NCT07262619 on ClinicalTrials.gov

6. Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

   This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy. Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Jupiter Medical Center/ Anderson Family Cancer Institute, Jupiter, Florida

   Locations

   54 in total

   Run by

   Pfizer

   See if you can join NCT07578649 on ClinicalTrials.gov

7. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

   This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   St. Elizabeth Healthcare, Edgewood, Kentucky

   Locations

   17 in total

   Run by

   LigaChem Biosciences, Inc.

   See if you can join NCT06774963 on ClinicalTrials.gov

8. Avera Cancer Sequencing and Analytics Protocol (ASAP)

   The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Avera Cancer Institute - Marshall, Marshall, Minnesota

   Locations

   6 in total

   Run by

   Avera McKennan Hospital & University Health Center

   See if you can join NCT05142033 on ClinicalTrials.gov

9. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalatio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute, Los Angeles, California

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

10. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

    This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    25 in total

    Run by

    Terremoto Biosciences Inc.

    See if you can join NCT07109726 on ClinicalTrials.gov

11. A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

    This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Broward Health Medical Center, Fort Lauderdale, Florida

    Locations

    86 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT07022483 on ClinicalTrials.gov

12. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    96 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

13. A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

    The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-ti…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCSF - Helen Diller Family Comprehensive Cancer Center, San Francisco, California

    Locations

    5 in total

    Run by

    Outpace Bio, Inc.

    See if you can join NCT07664735 on ClinicalTrials.gov

14. A Phase 1 Study of the Safety and Tolerability of CTX-10726

    This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Arizona, Phoenix, Arizona

    Locations

    8 in total

    Run by

    Compass Therapeutics

    See if you can join NCT07419841 on ClinicalTrials.gov

15. Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

    This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6. Part 1A will determine the safety, tolerability, pharmacokinetics (PK), and preliminar…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI at Florida Cancer Specialists, Orlando, Florida

    Locations

    6 in total

    Run by

    Sutro Biopharma, Inc.

    See if you can join NCT07807345 on ClinicalTrials.gov

16. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    88 in total

    Run by

    Artios Pharma Ltd

    See if you can join NCT04657068 on ClinicalTrials.gov

17. A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

    This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    12 in total

    Run by

    Cogent Biosciences, Inc.

    See if you can join NCT07383506 on ClinicalTrials.gov

18. Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

    Background: Endometrial cancer (EC) of the uterus is becoming more common in the US. Sometimes EC often has increased levels of a protein called HER2. Cancers with HER2 tend to be more aggressive and have poorer outcomes. Objective: To test 2 study drugs-a vaccine that targets HER2 (AdHER2DC) plus …

    Stage

    Phase 1

    Ages

    18 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT06253494 on ClinicalTrials.gov

19. A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

    The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or chemotherapy (doxoru…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    USC/Norris Cancer Center, Los Angeles, California

    Locations

    206 in total

    Run by

    BioNTech SE

    See if you can join NCT06340568 on ClinicalTrials.gov

20. Study of EV for Recurrent Endometrial Carcinoma

    This study is testing a drug called enfortumab vedotin in up to 12 patients with advanced endometrial (uterine) cancer that has worsened after previous treatments, including immunotherapy. The goal is to see how well the drug works and how safe it is. Patients will be treated for up to one year and…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin

    Run by

    William Bradley

    See if you can join NCT07139977 on ClinicalTrials.gov

21. Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

    This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (All Protocol Activites), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04774419 on ClinicalTrials.gov

22. Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy

    Endometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of chemotherapy and surgery. Standard of care chemotherapeutic treatment for uterine and ovarian cancers is toxic and severely disruptive to the p…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Northwestern Memorial Hospital, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT05990426 on ClinicalTrials.gov

23. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Denver, Colorado

    Locations

    6 in total

    Run by

    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

24. ALPINE: Maintenance Letrozole/Abemaciclib

    The purpose of this research study is to see if the study drugs abemaciclib and letrozole are effective and safe for participants with estrogen-receptor positive (ER+), mismatch repair proficient, tumor protein p53 (TP53) wild-type endometrial cancer. The names of the study drugs involved in this s…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Colorado Cancer Center, Aurora, Colorado

    Locations

    8 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06366347 on ClinicalTrials.gov

25. Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

    This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / N…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Alaska Womens Cancer Care, Anchorage, Alaska

    Locations

    123 in total

    Run by

    Canadian Cancer Trials Group

    See if you can join NCT05640999 on ClinicalTrials.gov